HPV E6/E7 mRNA联合HPV 16/18/45分型检测作为子宫颈癌机会性筛查方法的研究
研究纳入23 258例25~65岁妇女,评估Aptima HPV E6/E7 mRNA检测联合HPV 16/18/45分型作为子宫颈癌机会性筛查的可行性。Aptima HPV在检出HSIL及以上病变的敏感度和阴性预测值显著高于TCT,但特异度和阳性预测值显著低于TCT。Aptima HPV阳性尤其分型阳性者发生HSIL及以上病变的可能性大,在有条件的医院联合检测作为机会性筛查方法可行。
要点
- Aptima HPV检出HSIL及以上病变的敏感度98.11%,显著高于TCT的59.62%。
- Aptima HPV特异度87.16%,显著低于TCT的95.37%。
- Aptima HPV阳性尤其分型阳性者发生HSIL及以上病变可能性大。
核心结论
- Aptima HPV检测阳性特别是Aptima HPV-GT检测阳性的妇女发生组织学诊断≥HSIL病变的可能性大。
- 在有条件的医院,Aptima HPV联合Aptima HPV-GT检测作为子宫颈癌机会性筛查方法是可行的。
研究设计与样本
- 2016年10月至2017年10月在湖州市妇幼保健院体检中心及妇科门诊纳入23 258例25~65岁妇女,年龄(40±9)岁。
- 所有妇女行Aptima HPV检测,阳性者进一步行Aptima HPV-GT检测,并行液基薄层细胞学检查(TCT)。
- Aptima HPV阳性或TCT≥LSIL或临床症状明显者转诊阴道镜,必要时行子宫颈活检±子宫颈管搔刮术(ECC)。
主要发现
- Aptima HPV、HPV 16型、HPV 18/45型阳性率分别为14.00%(3 257/23 258)、1.85%(430/23 258)、0.86%(199/23 258)。
- 细胞学诊断NILM、ASCUS、LSIL、ASC-H、HSIL、鳞癌各组中,Aptima HPV、HPV 16型、HPV 18/45型阳性率均随细胞学级别增高而增高(P均=0.000)。
- 组织学诊断正常子宫颈、LSIL、HSIL、鳞癌各组中,Aptima HPV、HPV 16型、HPV 18/45型阳性率均随组织学级别增高而增高(P均=0.000)。
- 组织学≥HSIL组Aptima HPV阳性率98.11%(311/317),高于组织学≤LSIL组的12.84%(2 946/22 941),P=0.000。
- 组织学≥HSIL组Aptima HPV-GT阳性率58.36%(185/317),高于组织学≤LSIL组的1.91%(439/22 941),P=0.000。
关键数值与推荐
- 以组织学诊断为金标准筛查≥HSIL病变,Aptima HPV敏感度98.11% vs TCT 59.62%,P=0.000。
- Aptima HPV阴性预测值99.97% vs TCT 99.42%,P=0.000。
- Aptima HPV特异度87.16% vs TCT 95.37%,P=0.000。
- Aptima HPV阳性预测值9.55% vs TCT 15.10%,P=0.000。
临床怎么用
- 作者认为,在有条件的医院,Aptima HPV联合Aptima HPV-GT检测作为子宫颈癌机会性筛查方法是可行的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate Aptima HPV E6 and E7 mRNA assay (Aptima HPV) combined with Aptima HPV 16 and 18 or 45 (18/45) genotype assay (Aptima HPV-GT) as a means of cervical cancer opportunistic screening. Methods: From October 2016 to October 2017, a total of 23 258 women aged 25-65 years were enrolled in the physical examination center and gynecological clinic of Huzhou Maternity and Child Health Care Hospital. All the women had Aptima HPV tested, further Aptima HPV-GT testing for positive women and liquid-based thin layer cytology Thinprep cytologic test (TCT). Women with Aptima HPV (+) or ≥low-grade squamous intraepithelial lesion (LSIL) or obvious clinical symptoms (including vaginal bleeding after intercourse and watery, bloody vaginal discharge) were referred for colposcopy and further biopsy with or without endocervical curettage (ECC) if indicated. Expression of Aptima HPV, HPV 16 and HPV 18/45 with different cytological diagnostic groups and histological diagnosis groups were compared respectively. Sensitivity, specificity, positive predictive value and negative predictive value of Aptima HPV detection and TCT in identifying histological diagnosis of high-grade squamous intraepithelial lesion (HSIL) or worse (HSIL(+)) were compared. Results: (1) The positive rates of Aptima HPV, HPV 16 and HPV 18/45 were 14.00% (3 257/23 258), 1.85% (430/23 258) and 0.86% (199/23 258) respectively.The positive rates of Aptima HPV, HPV 16 and HPV 18/45 increased with cytology grading in squamous epithelium [negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASCUS), LSIL, atypical squamous cell cannot exclude HSIL (ASC-H), HSIL and squamous cell carcinoma (SCC), all P=0.000)]. According to histology results, the positive rates of Aptima HPV, HPV 16 and HPV 18/45 increased with histology grading in squamous epithelium (normal cervical tissue, LSIL, HSIL and SCC, all P=0.000). The positive rate of Aptima HPV was significantly higher in HSIL(+) group than that in the LSIL or better (LSIL(-)) group [98.11% (311/317) vs 12.84% (2 946/22 941), P=0.000]. The positive rate of Aptima HPV-GT was significantly higher in HSIL(+) group than that in LSIL(-) group [58.36% (185/317) vs 1.91% (439/22 941), P=0.000]. (2) Compared with cytology, Aptima HPV resulted in significant higher sensitivity (98.11% vs 59.62%, P=0.000) and negative predictive value (99.97% vs 99.42%, P=0.000), significant lower specificity (87.16% vs 95.37%, P=0.000) and positive predictive value (9.55% vs 15.10%, P=0.000) when identified HSIL(+). Conclusions: Women with Aptima HPV positive, especially those with Aptima HPV-GT positive, are more likely to have histological diagnosis of HSIL(+). Aptima HPV combined with Aptima HPV-GT is feasible as a means of cervical cancer opportunistic screening in tertiary hospitals. 目的: 探讨Aptima HPV检测(是基于HPV E6、E7 mRNA检测的方法)联合Aptima HPV 16型和HPV 18型和(或)45型(18/45型)分型(Aptima HPV-GT)检测作为子宫颈癌机会性筛查方法的可行性。 方法: 收集2016年10月—2017年10月在浙江省湖州市妇幼保健院体检或因妇科疾病就诊并自愿接受Aptima HPV检测(对其中HPV阳性妇女进一步行Aptima HPV-GT检测)和液基薄层细胞学检查(TCT)的妇女共23 258例,其年龄为(40±9)岁。对Aptima HPV检测阳性或TCT检查结果为低级别鳞状上皮内病变(LSIL)及以上病变或临床症状明显(如性交后出血、血性分泌物)的妇女行阴道镜检查,必要时在阴道镜定位下行子宫颈活检±子宫颈管搔刮(ECC)术。(1)分别比较不同细胞学诊断和组织学诊断妇女的Aptima HPV及Aptima HPV-GT检测结果。(2)以组织学诊断为"金标准",比较Aptima HPV检测与TCT检查对组织学诊断≥高级别鳞状上皮内病变(HSIL;包括HSIL、原位腺癌、腺癌、鳞癌和腺鳞癌)的筛查价值。 结果: (1)23 258例妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率分别为14.00%(3 257/23 258)、1.85%(430/23 258)和0.86%(199/23 258)。在细胞学诊断为未见上皮内病变或恶性病变(NILM)、未明确诊断意义的不典型鳞状上皮细胞(ASCUS)、LSIL、不能除外高度病变的不典型鳞状上皮细胞(ASC-H)、HSIL和鳞癌的妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率均随着细胞学诊断的病变级别的增高而明显增高(P均=0.000);在组织学诊断为正常子宫颈、LSIL、HSIL、鳞癌的妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率也均随着组织学诊断的病变级别的增高而明显增高(P均=0.000)。在组织学诊断≥HSIL病变中,Aptima HPV检测阳性率为98.11%(311/317),明显高于组织学诊断≤LSIL者[包括正常子宫颈及LSIL,为12.84%(2 946/22 941);P=0.000];Aptima HPV-GT检测阳性率为58.36%(185/317),明显高于组织学诊断≤LSIL者[1.91%(439/22 941);P=0.000]。(2)以组织学诊断为"金标准",在筛查组织学诊断≥HSIL的病变时,Aptima HPV检测的敏感度(分别为98.11%、59.62%)和阴性预测值(分别为99.97%、99.42%)均显著高于细胞学TCT检查(P均=0.000),但其特异度(分别为87.16%、95.37%)和阳性预测值(分别为9.55%、15.10%)则显著低于细胞学TCT检查(P均=0.000)。 结论: Aptima HPV检测阳性特别是Aptima HPV-GT检测阳性的妇女发生组织学诊断≥HSIL病变的可能性大。在有条件的医院,Aptima HPV联合Aptima HPV-GT检测作为子宫颈癌机会性筛查方法是可行的。.
引用
- Wang JJ, Dong J, Deng ZX, et al. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening]. Zhonghua Fu Chan Ke Za Zhi. 2019. PMID: 31154710. doi:10.3760/cma.j.issn.0529-567x.2019.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。